Skip to main content
Journal cover image

ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update.

Publication ,  Journal Article
Expert Panel on Urological Imaging; Allen, BC; Oto, A; Akin, O; Alexander, LF; Froemming, AT; Fulgham, PF; Halpern, DJ; Gettle, LM; Patel, BN ...
Published in: J Am Coll Radiol
May 2021

Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously undetected urothelial tumors, to identify metastatic disease, and to evaluate for complications of therapy. For surveillance, patients can be stratified into one of three groups: 1) nonmuscle invasive bladder cancer with no symptoms or additional risk factors; 2) nonmuscle invasive bladder cancer with symptoms or additional risk factors; and 3) muscle invasive bladder cancer. This document is a review of the current literature for urothelial cancer and resulting recommendations for surveillance imaging. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

Duke Scholars

Published In

J Am Coll Radiol

DOI

EISSN

1558-349X

Publication Date

May 2021

Volume

18

Issue

5S

Start / End Page

S126 / S138

Location

United States

Related Subject Headings

  • Urinary Bladder Neoplasms
  • United States
  • Societies, Medical
  • Radiology
  • Nuclear Medicine & Medical Imaging
  • Humans
  • Evidence-Based Medicine
  • Carcinoma, Transitional Cell
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Expert Panel on Urological Imaging, Allen, B. C., Oto, A., Akin, O., Alexander, L. F., Froemming, A. T., … Lockhart, M. E. (2021). ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update. J Am Coll Radiol, 18(5S), S126–S138. https://doi.org/10.1016/j.jacr.2021.02.011
Expert Panel on Urological Imaging, Brian C. Allen, Aytekin Oto, Oguz Akin, Lauren F. Alexander, Adam T. Froemming, Pat F. Fulgham, et al. “ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update.J Am Coll Radiol 18, no. 5S (May 2021): S126–38. https://doi.org/10.1016/j.jacr.2021.02.011.
Expert Panel on Urological Imaging, Allen BC, Oto A, Akin O, Alexander LF, Froemming AT, et al. ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update. J Am Coll Radiol. 2021 May;18(5S):S126–38.
Expert Panel on Urological Imaging, et al. “ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update.J Am Coll Radiol, vol. 18, no. 5S, May 2021, pp. S126–38. Pubmed, doi:10.1016/j.jacr.2021.02.011.
Expert Panel on Urological Imaging, Allen BC, Oto A, Akin O, Alexander LF, Froemming AT, Fulgham PF, Halpern DJ, Gettle LM, Maranchie JK, Patel BN, Patlas MN, Schieda N, Solanki A, Turkbey IB, Venkatesan AM, Yoo DC, Lockhart ME. ACR Appropriateness Criteria® Post-Treatment Surveillance of Bladder Cancer: 2021 Update. J Am Coll Radiol. 2021 May;18(5S):S126–S138.
Journal cover image

Published In

J Am Coll Radiol

DOI

EISSN

1558-349X

Publication Date

May 2021

Volume

18

Issue

5S

Start / End Page

S126 / S138

Location

United States

Related Subject Headings

  • Urinary Bladder Neoplasms
  • United States
  • Societies, Medical
  • Radiology
  • Nuclear Medicine & Medical Imaging
  • Humans
  • Evidence-Based Medicine
  • Carcinoma, Transitional Cell
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services